Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1106–1111. doi: 10.1038/bjc.1997.515

Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study.

A Nicolini 1, L Anselmi 1, C Michelassi 1, A Carpi 1
PMCID: PMC2228104  PMID: 9376274

Abstract

Between 1977 and 1993, 384 breast cancer patients were followed up post-operatively every 4 or 6 months with a serum tumour marker panel (CEA-TPA-CA15-3) and the usual imaging techniques. Twenty-eight patients were treated 13.5 +/- 10 months (mean +/- s.d.) before the clinical and/or radiological occurrence of distant metastases that were suspected because of an increase in the tumour markers (patients treated 'early'). Their outcome was compared with that of 22 similar patients who were treated only after a definite radiological diagnosis was achieved (patients treated 'not early'). The median survivals from mastectomy and salvage treatment were also compared for the two groups. The groups were similar for all the major prognostic factors (menopause, staging, hormone dependency). In the group treated 'early', the lead time from the tumour marker increase to the clinical and radiological signs of metastases was significantly longer than that of the group not treated 'early' (13.5 +/- 10 vs 3.4 +/- 2.8 months respectively; P < 0.001 by unpaired t-test). For patients treated 'early', the survival curves up to 30 months after salvage treatment and up to 72 months after mastectomy showed greater survival than those for the patients treated later (42.9% vs 13.6% and 42.9% vs 22.7% respectively; P = 0.04 in both instances). These data suggest that treatment triggered by rising tumour markers before clinical and/or radiological appearance of distant metastases can be useful in prolonging both the asymptomatic interval and the duration of response of some relapsed patients. Randomized prospective trials must be encouraged to confirm these data and to better evaluate the effect on the disease-free survival (DFS) and overall survival (OS) of 'early' salvage treatment protocols.

Full text

PDF
1109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adair F., Berg J., Joubert L., Robbins G. F. Long-term followup of breast cancer patients: the 30-year report. Cancer. 1974 Apr;33(4):1145–1150. doi: 10.1002/1097-0142(197404)33:4<1145::aid-cncr2820330438>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  2. Andreoli C., Buranelli F., Campa T., Costa A., Magni A., Pizzichetta M., Ciatto S. Chest x-ray survey in breast cancer follow-up--a contrary view. Tumori. 1987 Oct 31;73(5):463–465. doi: 10.1177/030089168707300506. [DOI] [PubMed] [Google Scholar]
  3. Bishop H. M., Blamey R. W., Morris A. H., Rose D. H., Preston B., Lane J., Doyle P. J. Bone scanning: its lack of value in the follow-up of patients with breast cancer. Br J Surg. 1979 Oct;66(10):752–754. doi: 10.1002/bjs.1800661020. [DOI] [PubMed] [Google Scholar]
  4. Black W. C., Welch H. G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993 Apr 29;328(17):1237–1243. doi: 10.1056/NEJM199304293281706. [DOI] [PubMed] [Google Scholar]
  5. Bruinvels D. J., Stiggelbout A. M., Kievit J., van Houwelingen H. C., Habbema J. D., van de Velde C. J. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994 Feb;219(2):174–182. doi: 10.1097/00000658-199402000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ciatto S., Rosselli Del Turco M., Pacini P., Mustacchi G., Simonis M., Sismondi P., Giardina G., Belsanti V., Aristei C., Molino A. M. Early detection of breast cancer recurrences through periodic follow-up--is it useless? Tumori. 1985 Aug 31;71(4):325–329. doi: 10.1177/030089168507100402. [DOI] [PubMed] [Google Scholar]
  7. Dixon A. R., Jackson L., Chan S. Y., Badley R. A., Blamey R. W. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer. 1993 Jul;68(1):181–185. doi: 10.1038/bjc.1993.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dixon A. R., Price M. R., Hand C. W., Sibley P. E., Selby C., Blamey R. W. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3. Br J Cancer. 1993 Nov;68(5):947–949. doi: 10.1038/bjc.1993.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Einstein AB., Jr Hormonal Therapy for Prostate Cancer: When to Use It. Cancer Control. 1995 Jan;2(1):32–36. [PubMed] [Google Scholar]
  10. Horton J. Follow-up of breast cancer patients. Cancer. 1984 Feb 1;53(3 Suppl):790–797. doi: 10.1002/1097-0142(19840201)53:3+<790::aid-cncr2820531330>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  11. Nicolini A., Carpi A., Di Marco G., Giuliani L., Giordani R., Palla S. A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer. 1989 May 15;63(10):2037–2046. doi: 10.1002/1097-0142(19890515)63:10<2037::aid-cncr2820631028>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  12. Nicolini A., Colombini C., Luciani L., Carpi A., Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991 Jul;64(1):154–158. doi: 10.1038/bjc.1991.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994 May 25;271(20):1593–1597. doi: 10.1001/jama.271.20.1593. [DOI] [PubMed] [Google Scholar]
  14. Rutgers E. J., van Slooten E. A., Kluck H. M. Follow-up after treatment of primary breast cancer. Br J Surg. 1989 Feb;76(2):187–190. doi: 10.1002/bjs.1800760227. [DOI] [PubMed] [Google Scholar]
  15. Tomin R., Donegan W. L. Screening for recurrent breast cancer--its effectiveness and prognostic value. J Clin Oncol. 1987 Jan;5(1):62–67. doi: 10.1200/JCO.1987.5.1.62. [DOI] [PubMed] [Google Scholar]
  16. Tubiana M., Koscielny S. Cell kinetics, growth rate and the natural history of breast cancer. The Heuson Memorial Lecture. Eur J Cancer Clin Oncol. 1988 Jan;24(1):9–14. doi: 10.1016/0277-5379(88)90170-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES